A double-blind RCT shows cord blood stem cells improved social cognition in children with autism. Here's what parents need to know about the latest research, safety data, and treatment process.
A 2025 meta-analysis of 52 studies, real-world Taiwan data, and Mayo Clinic intraarterial delivery results — what nephrologists need to know about MSCs and CKD.
A medical review of MSC-based and MSC-derived EV therapies for idiopathic pulmonary fibrosis, covering meta-analysis data, immune-cloaked cell engineering, nebulized exosome delivery, gut-lung axis mechanisms, and active clinical trials.
The 2026 evidence base for mesenchymal stem cell therapy in ischemic stroke includes a 26-study umbrella review and an 18-RCT network meta-analysis of 1,006 patients. MSCs were the only cell type to significantly reduce mortality. This medical review synthesizes the latest clinical data, mechanisms, active trials, and translational barriers.
Research shows MSC activity drops 40% by age 50. Learn what changes inside aging cells and three emerging therapies showing real results in 2026 clinical trials.
A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.
Japan approved the world’s first MSC therapy for spinal cord injury in 2018. Here’s what six years of real-world data and 2026 mechanism research tell us about where MSC therapy for SCI actually stands.
Planning a trip to Bangkok for stem cell therapy involves more than just scheduling your procedure date. International patients need to know: What does the post-treatment recovery week actually look like? Whether receiving intravenous (IV) infusions or targeted joint injections, the vast majority of patients experience minimal downtime. Here is a...
Diabetic ED, post-prostatectomy ED, PDE5 non-responders — here’s what 2026 trials and clinical experience show for stem cell therapy: who is a candidate, what the procedure looks like, what it costs, and what to expect.
MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for real patients.
English 
Chinese 
Russian 
French